Examination of the role of MRI in multiple sclerosis: A problem orientated approach

Results and Problems in Cell Differentiation

Volumn 51, Issue , 2010, Pages 287-301

  McFarland, Henry F ^a  

^a NATIONAL INSTITUTE OF NEUROLOGICAL DISORDERS AND STROKE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CONTRAST MEDIUM; DIAGNOSTIC AGENT;

ARTICLE; BRAIN; CLINICAL TRIAL; DISABILITY; HUMAN; METHODOLOGY; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; PATHOLOGY; PATHOPHYSIOLOGY; PROGNOSIS; CLINICAL TRIAL (TOPIC); DIAGNOSTIC USE; PROCEDURES;

BRAIN; CLINICAL TRIALS AS TOPIC; CONTRAST MEDIA; DISABILITY EVALUATION; HUMANS; MAGNETIC RESONANCE IMAGING; MULTIPLE SCLEROSIS; PROGNOSIS;

EID: 77956915571     PISSN: 00801844     EISSN: 18610412     Source Type: Book Series    
DOI: 10.1007/400_2009_33     Document Type: Article

References (65)

1. Albert PS, McFarland HF, Smith ME, Frank JA (1994) Time series for modelling counts from a relapsing-remitting disease: application to modelling disease activity in multiple sclerosis. Stat Med 13:453-466
2. Allen IV, Glover G, Anderson R (1981) Abnormalities in the macroscopically normal white matter in cases of mild or spinal multiple sclerosis (MS). Acta Neuropathol Suppl 7:176-178
3. Altmann DR, Jasperse B, Barkhof F et al (2009) Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. Neurology 72:595-601
4. Bagnato F, Jeffries N, Richert ND et al (2003) Evolution of T1 black holes in patients with multiple sclerosis imaged monthly for 4 years. Brain 126:1782-1789
5. Bagnato F, Butman JA, Gupta S et al (2006) In vivo detection of cortical plaques by MR imaging in patients with multiple sclerosis. AJNR Am J Neuroradiol 27:2161-2167
6. Bagnato F, Yao B, Cantor F et al (2009) Multisequence-imaging protocols to detect cortical lesions of patients with multiple sclerosis: Observations from a post-mortem 3 Tesla imaging study. J Neurol Sci
7. Barkhof F, Valk J, Hommes OR et al (1992) Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. AJNR Am J Neuroradiol 13:1257-1259
8. Barkhof F, Filippi M, Miller DH et al (1997) Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. Brain 120(Pt 11):2059-2069
9. Bendszus M, Ladewig G, Jestaedt L et al (2008) Gadofluorine M enhancement allows more sensitive detection of inflammatory CNS lesions than T2-w imaging: a quantitative MRI study. Brain 131:2341-2352
10. Benedict RH, Weinstock-Guttman B, Fishman I et al (2004) Prediction of neuropsychological impairment in multiple sclerosis: comparison of conventional magnetic resonance imaging measures of atrophy and lesion burden. Arch Neurol 61:226-230
11. Bielekova B, Lincoln A, McFarland H, Martin R (2000a) Therapeutic potential of phosphodiesterase-4 and -3 inhibitors in Th1-mediated autoimmune diseases. J Immunol 164:1117-1124
12. Bielekova B, Goodwin B, Richert N et al (2000b) Encephalitogenic potential of the myelin basic protein peptide (amino acids 83-99) in multiple sclerosis: results of a phase II clinical trial with an altered peptide ligand. Nat Med 6:1167-1175
13. Bielekova B, Richert N, Howard T et al (2004) Humanized anti-CD25 (daclizumab) inhibits disease activity in multiple sclerosis patients failing to respond to interferon beta. Proc Natl Acad Sci USA 101:8705-8708
14. Bielekova B, Howard T, Packer AN et al (2009) Effect of anti-CD25 antibody daclizumab in the inhibition of inflammation and stabilization of disease progression in multiple sclerosis. Arch Neurol 66:483-489
15. Bo L, Geurts JJ, van der Valk P et al (2007) Lack of correlation between cortical demyelination and white matter pathologic changes in multiple sclerosis. Arch Neurol 64:76-80
16. Coles A, Deans J, Compston A (2004) Campath-1H treatment of multiple sclerosis: lessons from the bedside for the bench. Clin Neurol Neurosurg 106:270-274
17. Coles AJ, Cox A, Le Page E et al (2006) The window of therapeutic opportunity in multiple sclerosis: evidence from monoclonal antibody therapy. J Neurol 253:98-108
18. Coles AJ, Compston DA, Selmaj KW et al (2008) Alemtuzumab vs. interferon beta-1a in early multiple sclerosis. N Engl J Med 359:1786-1801
19. Filippi M, Rocca MA, Martino G et al (1998) Magnetization transfer changes in the normal appearing white matter precede the appearance of enhancing lesions in patients with multiple sclerosis. Ann Neurol 43:809-814
20. Filippi M, Rocca MA, Sormani MP et al (1999) Short-term evolution of individual enhancing MS lesions studied with magnetization transfer imaging. Magn Reson Imaging 17:979-984
21. Fisher E, Lee JC, Nakamura K, Rudick RA (2008) Gray matter atrophy in multiple sclerosis: a longitudinal study. Ann Neurol 64:255-265
22. Fisniku LK, Brex PA, Altmann DR et al (2008a) Disability and T2 MRI lesions: a 20-year followup of patients with relapse onset of multiple sclerosis. Brain 131:808-817
23. Fisniku LK, Chard DT, Jackson JS et al (2008b) Gray matter atrophy is related to long-term disability in multiple sclerosis. Ann Neurol 64:247-254
24. Frank JA, Stone LA, Smith ME et al (1994) Serial contrast-enhanced magnetic resonance imaging in patients with early relapsing-remitting multiple sclerosis: implications for treatment trials. Ann Neurol 36 Suppl:S86-90
25. Geurts JJ (2008) Is progressive multiple sclerosis a gray matter disease? Ann Neurol 64:230-232
26. Geurts JJ, Barkhof F (2008) Grey matter pathology in multiple sclerosis. Lancet Neurol 7:841-851
27. Goodkin DE, Rooney WD, Sloan R et al (1998) A serial study of new MS lesions and the white matter from which they arise. Neurology 51:1689-1697
28. Griffin CM, Dehmeshki J, Chard DT et al (2002) T1 histograms of normal-appearing brain tissue are abnormal in early relapsing-remitting multiple sclerosis. Mult Scler 8:211-216
29. Guo AC, MacFall JR, Provenzale JM (2002) Multiple sclerosis: diffusion tensor MR imaging for evaluation of normal-appearing white matter. Radiology 222:729-736
30. Harris JO, Frank JA, Patronas N et al (1991) Serial gadolinium-enhanced magnetic resonance imaging scans in patients with early, relapsing-remitting multiple sclerosis: implications for clinical trials and natural history. Ann Neurol 29:548-555
31. Kappos L, Moeri D, Radue EW et al (1999) Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. Gadolinium MRI Meta-analysis Group. Lancet 353:964-969
32. Katz D, Taubenberger JK, Cannella B et al (1993) Correlation between magnetic resonance imaging findings and lesion development in chronic, active multiple sclerosis. Ann Neurol 34:661-669
33. Kidd D, Barkhof F, McConnell R et al (1999) Cortical lesions in multiple sclerosis. Brain 122(Pt 1):17-26
34. Kolind SH, Laule C, Vavasour IM et al (2008) Complementary information from multi-exponential T2 relaxation and diffusion tensor imaging reveals differences between multiple sclerosis lesions. Neuroimage 40:77-85
35. Kutzelnigg A, Lucchinetti CF, Stadelmann C et al (2005) Cortical demyelination and diffuse white matter injury in multiple sclerosis. Brain 128:2705-2712
36. Linker RA, Kroner A, Horn T et al (2006) Iron particle-enhanced visualization of inflammatory central nervous system lesions by high resolution: preliminary data in an animal model. AJNR Am J Neuroradiol 27:1225-1229
37. Losseff NA, Miller DH, Kidd D, Thompson AJ (2001) The predictive value of gadolinium enhancement for long term disability in relapsing-remitting multiple sclerosis-preliminary results. Mult Scler 7:23-25
38. McDonald WI, Compston A, Edan G et al (2001) Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 50:121-127
39. McFarland HF, Frank JA, Albert PS et al (1992) Using gadolinium-enhanced magnetic resonance imaging lesions to monitor disease activity in multiple sclerosis. Ann Neurol 32:758-766
40. McFarland HF, Barkhof F, Antel J, Miller DH (2002) The role of MRI as a surrogate outcome measure in multiple sclerosis. Mult Scler 8:40-51
41. Miller DH, Barkhof F, Nauta JJ (1993) Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. Brain 116(Pt 5):1077-1094
42. Muraro PA, Wandinger KP, Bielekova B et al (2003) Molecular tracking of antigen-specific T cell clones in neurological immune-mediated disorders. Brain 126:20-31
43. Neema M, Arora A, Healy BC et al (2009) Deep gray matter involvement on brain MRI scans is associated with clinical progression in multiple sclerosis. J Neuroimaging 19:3-8
44. Nelson F, Poonawalla AH, Hou P et al (2007) Improved identification of intracortical lesions in multiple sclerosis with phase-sensitive inversion recovery in combination with fast double inversion recovery MR imaging. AJNR Am J Neuroradiol 28:1645-1649
45. Nelson F, Poonawalla A, Hou P et al (2008) 3D MPRAGE improves classification of cortical lesions in multiple sclerosis. Mult Scler 14:1214-1219
46. Peterson JW, Bo L, Mork S et al (2001) Transected neurites, apoptotic neurons, and reduced inflammation in cortical multiple sclerosis lesions. Ann Neurol 50:389-400
47. Petkau J, Reingold SC, Held U et al (2008) Magnetic resonance imaging as a surrogate outcome for multiple sclerosis relapses. Mult Scler 14:770-778
48. Polman CH, Reingold SC, Edan G et al (2005) Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 58:840-846
49. Richert ND, Frank JA (1999) Magnetization transfer imaging to monitor clinical trials in multiple sclerosis. Neurology 53:S29-32
50. Richert ND, Ostuni JL, Bash CN et al (2001) Interferon beta-1b and intravenous methylprednisolone promote lesion recovery in multiple sclerosis. Mult Scler 7:49-58
51. Riva M, Ikonomidou VN, Ostuni JJ et al (2009) Tissue-specific imaging is a Robust methodology to differentiate in vivo T1 black holes with advanced multiple sclerosis-induced damage. AJNR Am J Neuroradiol 30(7):1394-1401
52. Rocca MA, Agosta F, Sormani MP et al (2008) A three-year, multi-parametric MRI study in patients at presentation with CIS. J Neurol 255:683-691
53. Roosendaal SD, Geurts JJ, Vrenken H et al (2009) Regional DTI differences in multiple sclerosis patients. Neuroimage 44:1397-1403
54. Schmierer K, Scaravilli F, Altmann DR et al (2004) Magnetization transfer ratio and myelin in postmortem multiple sclerosis brain. Ann Neurol 56:407-415
55. Schmierer K, Wheeler-Kingshott CA, Boulby PA et al (2007) Diffusion tensor imaging of post mortem multiple sclerosis brain. Neuroimage 35:467-477
56. Sicotte NL, Kern KC, Giesser BS et al (2008) Regional hippocampal atrophy in multiple sclerosis. Brain 131:1134-1141
57. Smith ME, Stone LA, Albert PS et al (1993) Clinical worsening in multiple sclerosis is associated with increased frequency and area of gadopentetate dimeglumine-enhancing magnetic resonance imaging lesions. Ann Neurol 33:480-489
58. Stone LA, Frank JA, Albert PS et al (1995) The effect of interferon-beta on blood-brain barrier disruptions demonstrated by contrast-enhanced magnetic resonance imaging in relapsingremitting multiple sclerosis. Ann Neurol 37:611-619
59. Tintore M, Rovira A, Martinez MJ et al (2000) Isolated demyelinating syndromes: comparison of different MR imaging criteria to predict conversion to clinically definite multiple sclerosis. AJNR Am J Neuroradiol 21:702-706
60. van den Elskamp IJ, Lembcke J, Dattola V et al (2008) Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. Mult Scler 14:764-769
61. van Walderveen MA, Kamphorst W, Scheltens P et al (1998) Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. Neurology 50:1282-1288
62. Vellinga MM, Oude Engberink RD, Seewann A et al (2008) Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. Brain 131:800-807
63. Vrenken H, Barkhof F, Uitdehaag BM et al (2005) MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. Magn Reson Med 53:256-266
64. Werring DJ, Clark CA, Barker GJ et al (1999) Diffusion tensor imaging of lesions and normalappearing white matter in multiple sclerosis. Neurology 52:1626-1632
65. Yu CS, Lin FC, Liu Y et al (2008) Histogram analysis of diffusion measures in clinically isolated syndromes and relapsing-remitting multiple sclerosis. Eur J Radiol 68:328-334